VBWG - Resource Item

Resources

Quick Order
About Create Profile Login
Email: Password:

Slide Lecture Programs
2006 Core Curriculum cash advance cash advance
Targeting Insulin Resistance for Vascular Protection cash advance cash advance
July 31, 2006
Table of Contents - 120 slides
No.	Title
1	Targeting Insulin Resistance for Vascular Protection cash advance cash advance
2	Contents cash advance cash advance
3	Vascular Consequences of Diabetes and Insulin Resistance cash advance cash advance
4	One third of adults with diabetes are undiagnosed cash advance cash advance
5	Rising prevalence of diabetes cash advance cash advance
6	Parallel epidemics of diabetes and obesity cash advance cash advance
7	90% of patients with newly-diagnosed diabetes are overweight or obese cash advance cash advance
8	IFG/IGT: Challenge for prevention cash advance cash advance
9	"Ticking clock" hypothesis: Glucose abnormalities increase CV risk cash advance cash advance
10	DECODE: IGT increases mortality risk cash advance cash advance
11	CHD risk appears to begin at low blood glucose levels cash advance cash advance
12	Continuum of CV risk: Reason for early intervention in patients with IFG/IGT cash advance cash advance
13	Even mild glucose elevations increase mortality in patients undergoing PCI cash advance cash advance
14	IGT and undiagnosed DM2 are common in acute MI and stroke cash advance cash advance
15	Risk of endothelial dysfunction increases at FG 110-125 mg/dL cash advance cash advance
16	Impaired macrovascular reactivity in people at risk for type 2 diabetes cash advance cash advance
17	Insulin resistance: Risk factor for CV disease cash advance cash advance
18	Insulin resistance and atherosclerosis cash advance cash advance
19	Who has insulin resistance? cash advance cash advance
20	Insulin resistance is an independent predictor of HF cash advance cash advance
21	Insulin resistance increases risk of chronic kidney disease (CKD) cash advance cash advance
22	Development of insulin resistance in obesity-induced inflammation and stress cash advance cash advance
23	Visceral obesity cash advance cash advance
24	Visceral fat independently predicts mortality cash advance cash advance
25	CRP levels show positive correlation with visceral obesity cash advance cash advance
26	Shared CV risk between insulin resistance and visceral obesity cash advance cash advance
27	Metabolically active molecules link obesity and atherosclerosis cash advance cash advance
28	Antiatherogenic effects of adiponectin cash advance cash advance
29	Visceral obesity and adiponectin cash advance cash advance
30	Inverse relationship between baseline adiponectin level and MI risk cash advance cash advance
31	Shared metabolic abnormalities with insulin resistance and endothelial dysfunction cash advance cash advance
32	PPAR activation and atherosclerosis: A hypothesis cash advance cash advance
33	Peroxisome proliferator-activator receptors (PPARs) cash advance cash advance
34	PPARs: Overview cash advance cash advance
35	Beyond fat and glucose: Potential for CV benefits with PPAR-gamma agonists cash advance cash advance
36	Obesity induces inflammatory changes in adipose tissue cash advance cash advance
37	Macrophage and adipocyte similarities cash advance cash advance
38	PPAR signaling pathways influence macrophage gene expression and foam-cell formation cash advance cash advance
39	PPAR-gamma agonists improve endothelial vasodilation and decrease inflammation cash advance cash advance
40	PPAR-gamma agonists impact inflammatory markers and adiponectin cash advance cash advance
41	Added benefit of BP reduction with PPAR-gamma agonists cash advance cash advance
42	PPAR-gamma agonists increase collagen content-potentially improving plaque stability cash advance cash advance
43	Potential vascular benefits of PPAR activation cash advance cash advance
44	CV Risk Reduction, Diabetes Prevention, and TZDs cash advance cash advance
45	UKPDS 34: Intensive glucose control and CV protection cash advance cash advance
46	DCCT/EDIC: Lower glucose = lower long-term CV risk cash advance cash advance
47	DCCT/EDIC: Intensive glucose control reduces long-term CV risk cash advance cash advance
48	DCCT/EDIC: Intensive treatment slows renal changes cash advance cash advance
49	Vascular effects of thiazolidinediones (TZDs) cash advance cash advance
50	TZDs impact carotid IMT cash advance cash advance
51	TZD impact on restenosis in type 2 diabetes cash advance cash advance
52	TZDs consistently reduce restenosis after coronary stenting in patients with diabetes cash advance cash advance
53	Surrogate outcome results driving major TZD Trials cash advance cash advance
54	Major TZD outcome trials cash advance cash advance
55	Major TZD outcome trials cash advance cash advance
56	PROactive: Study design cash advance cash advance
57	PROactive: CV history at baseline cash advance cash advance
58	PROactive: CV medications at baseline cash advance cash advance
59	PROactive: Nonsignificant reduction in primary outcome cash advance cash advance
60	PROactive: Significant reduction in secondary outcome cash advance cash advance
61	PROactive: Subgroup analysis--Previous MI cash advance cash advance
62	PROactive: HF hospitalization and mortality cash advance cash advance
63	PROactive vs landmark clinical trials: Comparative benefit in patients with diabetes cash advance cash advance
64	PROactive in perspective cash advance cash advance
65	Fluid retention after TZD use tends to be peripheral cash advance cash advance
66	Managing TZD-related fluid retention cash advance cash advance
67	Collecting duct (CD) PPAR-gamma: Potential mechanism for volume expansion cash advance cash advance
68	TZDs associated with lower mortality cash advance cash advance
69	TZDs in type 2 diabetes and HF cash advance cash advance
70	Major TZD outcome trials cash advance cash advance
71	DREAM: Background and study objective cash advance cash advance
72	RAAS modulation reduces new-onset diabetes cash advance cash advance
73	TRIPOD: Treating insulin resistance reduces incidence of type 2 diabetes cash advance cash advance
74	TZDs blunt diabetes progression cash advance cash advance
75	DREAM: Study design cash advance cash advance
76	DREAM: 2 x 2 factorial design cash advance cash advance
77	DREAM: Inclusion criteria cash advance cash advance
78	DREAM: Key exclusion criteria cash advance cash advance
79	DREAM: Baseline characteristics cash advance cash advance
80	DREAM: Baseline glucose status cash advance cash advance
81	DREAM: Beyond diabetes prevention cash advance cash advance
82	DREAM: Substudies cash advance cash advance
83	ADOPT: Study objective cash advance cash advance
84	ADOPT: Study design cash advance cash advance
85	CHICAGO: Study objective cash advance cash advance
86	CHICAGO: Study design cash advance cash advance
87	Clinical Imperatives When Treating Patients with Diabetes cash advance cash advance
88	Diabetes, IFG, IGT: Diagnostic criteria cash advance cash advance
89	AHA/ACC/ADA: Multiple risk reduction in diabetes cash advance cash advance
90	AACE: Managing diabetes cash advance cash advance
91	AHA/ACC secondary prevention guidelines: Diabetes management cash advance cash advance
92	DPP: Benefit of diet/exercise or metformin on diabetes prevention in at-risk patients cash advance cash advance
93	DPP: Benefit of diet/exercise or metformin on diabetes by race/ethnicity cash advance cash advance
94	3-Week diet + exercise yield favorable metabolic changes cash advance cash advance
95	3-Week diet + exercise reduce proatherogenic factors cash advance cash advance
96	Beyond lifestyle: Aggressive medical therapy in diabetes cash advance cash advance
97	Steno-2 supports aggressive multifactorial intervention in type 2 diabetes cash advance cash advance
98	Steno-2: Multifactorial intervention on CV outcomes cash advance cash advance
99	Steno-2: Better risk factor control with intensive therapy cash advance cash advance
100	Steno-2: Effects of multifactorial intervention on microvascular and neuropathic outcomes cash advance cash advance
101	Benefits of aggressive LDL-C lowering in diabetes cash advance cash advance
102	HPS: Statin beneficial irrespective of baseline lipid level and diabetes status cash advance cash advance
103	ASCOT-LLA: Atorvastatin reduces CV events in patients with diabetes and hypertension cash advance cash advance
104	MICRO-HOPE, PERSUADE: ACEI reduces CV events in diabetes cash advance cash advance
105	TZD + statin: Favorable effects on inflammatory markers and adiponectin cash advance cash advance
106	Principle mechanisms of action for oral diabetic agents cash advance cash advance
107	Oral antihyperglycemic agents cash advance cash advance
108	Beyond glucose lowering: Effects of antidiabetic agents cash advance cash advance
109	TZD vs sulfonylurea: Glycemic control over time cash advance cash advance
110	TZD + sulfonylurea efficacy in type 2 diabetes cash advance cash advance
111	PROactive: Reduced requirement for insulin use cash advance cash advance
112	Sulfonylurea + TZD or metformin: Comparison of lipid and renal effects cash advance cash advance
113	TZDs and metformin reduce risk of MI cash advance cash advance
114	Improving blood glucose control: Potential role of combination therapy cash advance cash advance
115	DPP-IV inhibitors cash advance cash advance
116	DPP-IV inhibitors, GLP-1 analogs: New classes of antidiabetic agents cash advance cash advance
117	AMIGO trials: GLP-1 analog in type 2 diabetes cash advance cash advance
118	Managing diabetes as a CHD equivalent: ABCs of coronary prevention cash advance cash advance
119	Proatherogenic effects of insulin resistance cash advance cash advance
120	Summary: Expanding risk factor control to enhance CV outcomes cash advance cash advance


Home \| Literature Update \| Journal Link \| Resources \| Meeting Highlights \| Members \| About VBWG \| Web Links